Craft
Lundbeck

Lundbeck

Stock Price

KR172.7

2022-06-09

Market Capitalization

KR34.3 B

2022-06-09

Revenue

KR18.2 B

FY, 2022

Lundbeck Summary

Company summary

Overview
Lundbeck engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. The Company offers pharmaceutical products for the treatment of Alzheimer's disease, depression, Parkinson's disease, Schizophrenia, alcohol dependence, anxiety, Bipolar I disorder, Epilepsy, Huntington’s disease, and symptomatic neurogenic orthostatic hypotension.
Type
Public
Status
Active
Founded
1915
HQ
København, DK | view all locations
Website
http://www.lundbeck.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Deborah Dunsire

    Deborah Dunsire, President & CEO

    • Lars Søren Rasmussen

      Lars Søren Rasmussen, Chairman of the Board Member, Audit Committee Chairman

      • Jeremy Max Levin

        Jeremy Max Levin, Chairman, Scientific Committee

        • Henrik Andersen

          Henrik Andersen, Chairman, Audit Committee

          LocationsView all

          59 locations detected

          • København HQ

            Denmark

            Ottiliavej 9

          • Deerfield, IL

            United States

            6 Parkway N

          • CNG, CABA

            Argentina

            Heredia 553

          • Macquarie Park, NSW

            Australia

            Innovation Rd

          • Wien, Wien

            Austria

            17 Mooslackengasse

          • Wien, Wien

            Austria

            Leopold-Ungar-Platz

          and 53 others

          Lundbeck Financials

          Summary financials

          Revenue (FY, 2022)
          kr18.2B
          Gross profit (FY, 2022)
          kr16.0B
          Net income (FY, 2022)
          kr1.9B
          Cash (FY, 2022)
          kr3.4B
          EBIT (FY, 2022)
          kr2.9B
          Enterprise value
          $36.5B

          Footer menu